Excipients are never just a line item. They decide how a formulation behaves, and we help our customers get that decision right from the first lab trial
Noel Dsa, Founder & Director
In pharmaceutical manufacturing, the quality of a finished formulation depends as much on the reliability of its raw materials as on the sophistication of its production processes. Excipients, often considered secondary to active pharmaceutical ingredients, play a critical role in determining formulation stability, performance, manufacturability and patient acceptability. As pharmaceutical and biopharmaceutical companies develop increasingly complex products, sourcing these materials has evolved beyond conventional procurement into a function demanding technical expertise, regulatory understanding and dependable supply chains.
Recognising this shift, Krest Chemicals was established in 2023 to address persistent gaps in specialised excipient sourcing. Positioned as a life sciences raw material supplier, the company combines access to specialised pharmaceutical excipients with application knowledge, responsive service and flexible procurement models. Its approach particularly addresses the requirements of large and mid-sized pharmaceutical manufacturers and R&D centres that often struggle with extended lead times, limited access to specialised grades and inadequate technical support.
Driving this vision is Krest Chemicals' Founder and Director Noel Dsa, who brings nearly 22 years of experience in pharmaceutical and biopharmaceutical excipients. Beginning his career in sales with an Indian distribution company, he subsequently worked with a multinational specialised excipient manufacturer, gaining exposure to global markets, regulatory requirements and complex qualification processes. His interactions with formulation scientists revealed an important industry reality: selecting the right excipient early can prevent costly complications during scale-up and stability studies. This understanding became central to Krest Chemicals' operating philosophy.
Building Supply Models Around Formulation Requirements
Unlike conventional distributors operating through standardised procurement arrangements, Krest Chemicals has developed two complementary business models: stock-and-sale and indenting. Both are designed to accommodate different purchasing volumes, development stages and delivery requirements.
Under its stock-and-sale model, the company maintains ready inventory of fast-moving and critical excipient grades at its Bhiwandi warehouse. This enables manufacturers to access smaller quantities for laboratory trials, pilot batches and urgent production requirements without waiting through extended procurement cycles. Inventory planning is guided by customer consumption patterns and manufacturer lead times, allowing the company to anticipate requirements rather than respond only after shortages arise.
The facility operates under a documented Quality Management System, follows Good Distribution Practices and is supervised by an in-house quality assurance team. Its warehouse has also been audited by customers with zero observations.
Krest Chemicals has built its operations around a stock-and-sale model, with an indenting model planned as the business grows. Together, these are designed to accommodate different purchasing volumes, development stages and delivery requirements.
Moving Beyond Distribution to Technical Partnership
Krest Chemicals differentiates itself through an approach that treats excipient sourcing as an extension of formulation development rather than a standalone commercial transaction. Its team works to understand the intended application, functional requirements and potential formulation challenges before recommending materials. Technical knowledge sharing, troubleshooting assistance and regulatory documentation support remain integral to customer engagement. Where specialised expertise is required, the company facilitates interactions between formulation teams and its manufacturing principals.
This involvement extends beyond initial trials into subsequent development and commercial production stages. The Founder continues to maintain direct relationships with key customers, regularly engaging with laboratories and manufacturing facilities. Excipients are never just a line item. They decide how a formulation behaves, and we help our customers get that decision right from the first lab trial
Equally important is the company's selective approach to manufacturer partnerships. “We work only with principals whose quality systems, manufacturing standards and documentation we have verified. We deliberately avoid competing product ranges, so our principals know we are fully committed to them and our customers get an honest recommendation," says Noel Dsa, Founder and Director.
Making Quality and Responsiveness Non- Negotiable
For pharmaceutical manufacturers, supply disruptions can affect production schedules, regulatory commitments and product availability. Krest Chemicals addresses these risks through documentation discipline, forecast-led stocking and structured customer communication.
Every shipment is supported by relevant quality and regulatory documentation, while the company assists customers with manufacturer-provided information during audits and compliance reviews. Its commitment to a 12-hour turnaround time for customer queries and support requests, within its operational scope, further reinforces its emphasis on responsiveness.
“Geopolitical uncertainty is pushing manufacturers to put supply resilience ahead of the lowest price. With formulations becoming more complex and regulations tighter, they need sourcing partners who understand the science, not just the logistics”, adds Noel Dsa.
Expanding Capabilities Without Compromising Customer Relationships
Looking ahead, Krest Chemicals intends to pursue depth before breadth. Its portfolio expansion will focus on specialised excipients for biologics, injectables, controlled-release formulations and nutraceuticals through carefully selected manufacturing partnerships.
Geographically, the company plans to strengthen its presence across pharmaceutical clusters in Madhya Pradesh, Telangana and Himachal Pradesh while developing opportunities in Bangladesh, Sri Lanka, Nepal and the Middle East. Further investments in warehousing capacity, technical support capabilities and digital tools will complement its expansion. The company also aims to become an authorised channel for international excipient manufacturers entering India, while supporting Indian manufacturers seeking export routes.
As formulations grow more complex, Krest Chemicals intends to remain the partner formulators turn to first. “The right excipient, chosen early, can save a customer months at scale-up,” says Noel Dsa. “We want to be the first call a formulator makes, not the last".